Rothschild Redburn: PODD Has 87% Upside! One Day Later: Never Mind, Downgrade to Neutral

On April 23, the Wall Street consensus on Insulet (PODD) was overwhelmingly bullish. Multiple analysts maintained Buy ratings with a consensus price target of $360—implying 87% upside for investors brave enough to hop in. The thesis: diabetes management is unsexy but profitable, and PODD had unassailable competitive moats. By April 24—one trading day later—analyst Issie Kirby at Rothschild & Co Redburn discovered those moats were apparently made of sand. The firm downgraded PODD from Buy to Neutral and slashed the price target 42% to $220, citing "eroding product moats and distribution concerns." What changed between April 23 and April 24? Absolutely nothing publicly disclosed—but that didn't stop the analyst from a full 180. By May 1, PODD had cratered 23.7% from its March highs. The moral: when a supposedly inviolable thesis crumbles overnight, it was never inviolable to begin with.